Contact
searchSearch
HMP Global
Login

Diffuse Large B-Cell Lymphoma Specialty Channel

Diffuse Large B-Cell Lymphoma
Specialty Channel
News
Cytokine and Chemokines as Predictive Biomarkers of CAR-T Therapy Outcomes in Large B-Cell Lymphoma
04/11/2025
Emily Estrada
Plasma cytokines and chemokine levels may be used as predictive biomarkers of CAR-T therapy response and toxicity among patients with large B-cell lymphoma.
Plasma cytokines and chemokine levels may be used as predictive biomarkers of CAR-T therapy response and toxicity among patients with large B-cell lymphoma.
Plasma cytokines and chemokine...
04/11/2025
Oncology
News
Odronextamab Demonstrates Durability and Safety for Relapsed/Refractory DLBCL
04/09/2025
Emily Estrada
Treatment for relapsed/refractory diffuse large B-cell lymphoma with odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy.
Treatment for relapsed/refractory diffuse large B-cell lymphoma with odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy.
Treatment for...
04/09/2025
Oncology
News
Effect of Timing of Bispecific Antibody Treatment for Patients With B-Cell Lymphomas Relapsing After CAR-T
03/24/2025
Emily Estrada
Following CAR-T therapy relapse, study findings suggest the timing of bispecific antibody treatment administration may be associated with improved responses among patients with B-cell lymphomas.
Following CAR-T therapy relapse, study findings suggest the timing of bispecific antibody treatment administration may be associated with improved responses among patients with B-cell lymphomas.
Following CAR-T therapy relapse,...
03/24/2025
Oncology
News
Brentuximab Vedotin Plus Lenalidomide and Rituximab Improves Survival For Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
03/17/2025
Emily Estrada
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
For patients with...
03/17/2025
Oncology
News
Presence of Circulating Lymphoma Cells Associated With Worse Survival Outcomes for Patients With Newly Diagnosed DLBCL
01/16/2025
Emily Estrada
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are...
01/16/2025
Oncology
Conference Coverage
Retreatment With R-CHOP-Like Therapy Effective in Late-Relapse DLBCL
12/07/2024
Meagan Thistle
In patients with late-relapse DLBCL, a retreatment strategy with R-CHOP-like therapy is a reasonable option and results in durable remission in a high proportion of patients, according to a retrospective study presented at the 2024 ASH Annual...
In patients with late-relapse DLBCL, a retreatment strategy with R-CHOP-like therapy is a reasonable option and results in durable remission in a high proportion of patients, according to a retrospective study presented at the 2024 ASH Annual...
In patients with late-relapse...
12/07/2024
Oncology
Conference Coverage
Time of CAR-T Cell Therapy Failure May Predict Outcomes of Bispecific Antibody Therapy Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
12/05/2024
Allison Casey
According to a retrospective, real-world study presented at the 2024 ASH Annual Meeting & Exposition, the timing of CAR-T cell therapy failure may predict the outcomes for bispecific antibody therapies for patients with relapsed/refractory...
According to a retrospective, real-world study presented at the 2024 ASH Annual Meeting & Exposition, the timing of CAR-T cell therapy failure may predict the outcomes for bispecific antibody therapies for patients with relapsed/refractory...
According to a retrospective,...
12/05/2024
Oncology
Quiz
Autologous Hematopoietic Cell Transplantation or CAR-T Therapy for Patients With Relapsed LBCL
09/30/2024
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to...
09/30/2024
Oncology
News
Autologous Hematopoietic Cell Transplantation Demonstrates Improved Outcomes Over CAR-T Among Patients With Relapsed LBCL Who Achieve Complete Remission
08/30/2024
Amber Denham
According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...
According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...
According to results from a...
08/30/2024
Oncology
News
IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology
Quiz
Induction Therapy With High-Dose Chemo, Autologous HSCT in Patients With PCNSL
04/11/2024
04/11/2024
Oncology

News

News
Cytokine and Chemokines as Predictive Biomarkers of CAR-T Therapy Outcomes in Large B-Cell Lymphoma
04/11/2025
Emily Estrada
Plasma cytokines and chemokine levels may be used as predictive biomarkers of CAR-T therapy response and toxicity among patients with large B-cell lymphoma.
Plasma cytokines and chemokine levels may be used as predictive biomarkers of CAR-T therapy response and toxicity among patients with large B-cell lymphoma.
Plasma cytokines and chemokine...
04/11/2025
Oncology
News
Odronextamab Demonstrates Durability and Safety for Relapsed/Refractory DLBCL
04/09/2025
Emily Estrada
Treatment for relapsed/refractory diffuse large B-cell lymphoma with odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy.
Treatment for relapsed/refractory diffuse large B-cell lymphoma with odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy.
Treatment for...
04/09/2025
Oncology
News
Effect of Timing of Bispecific Antibody Treatment for Patients With B-Cell Lymphomas Relapsing After CAR-T
03/24/2025
Emily Estrada
Following CAR-T therapy relapse, study findings suggest the timing of bispecific antibody treatment administration may be associated with improved responses among patients with B-cell lymphomas.
Following CAR-T therapy relapse, study findings suggest the timing of bispecific antibody treatment administration may be associated with improved responses among patients with B-cell lymphomas.
Following CAR-T therapy relapse,...
03/24/2025
Oncology
News
Brentuximab Vedotin Plus Lenalidomide and Rituximab Improves Survival For Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
03/17/2025
Emily Estrada
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
For patients with...
03/17/2025
Oncology
News
Presence of Circulating Lymphoma Cells Associated With Worse Survival Outcomes for Patients With Newly Diagnosed DLBCL
01/16/2025
Emily Estrada
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are...
01/16/2025
Oncology
News
Autologous Hematopoietic Cell Transplantation Demonstrates Improved Outcomes Over CAR-T Among Patients With Relapsed LBCL Who Achieve Complete Remission
08/30/2024
Amber Denham
According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...
According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...
According to results from a...
08/30/2024
Oncology
News
IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology
News
Short Induction Therapy Followed by High-Dose Chemotherapy and Autologous HSCT Demonstrates Activity for Older Patients With Primary Diffuse Large B-Cell CNS Lymphoma
04/09/2024

Amber Denham

Amber Denham
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short...
04/09/2024
Oncology
News
Lisocabtagene Maraleucel Shows Continued Efficacy, Manageable Safety for Patients with R/R LBCL
02/28/2024

Amber Denham

Amber Denham
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up...
02/28/2024
Oncology
News
Polatuzumab Vedotin Plus Rituximab and Lenalidomide Efficacy Among Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
02/21/2024
Amber Denham
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with...
02/21/2024
Oncology
FDA Approval
FDA Approves Penpulimab for Patients With Non-Keratinizing Nasopharyngeal Carcinoma
04/24/2025
Stephanie Holland
On April 23, 2025, the FDA has approved penpulimab plus chemotherapy for patients with metastatic non-keratinizing nasopharyngeal carcinoma.
On April 23, 2025, the FDA has approved penpulimab plus chemotherapy for patients with metastatic non-keratinizing nasopharyngeal carcinoma.
On April 23, 2025, the FDA has...
04/24/2025
Oncology
News
Lenvatinib-Based Regimens Demonstrate Efficacy, Safety Among Pre-Treated Patients With Metastatic Renal Cell Carcinoma
04/24/2025
Stephanie Holland
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective...
04/24/2025
Oncology
News
Palbociclib Plus Endocrine Therapy May Prolong Progression-Free Survival for Premenopausal Patients With HR-Positive, HER2-Negative Breast Cancer
04/23/2025
Stephanie Holland
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to extended follow-up...
04/23/2025
Oncology
News
Trastuzumab Rezetecan for Patients With HER2-Mutated Non-Small Cell Lung Cancer
04/22/2025
Stephanie Holland
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the...
04/22/2025
Oncology
News
Temozolomide as Potential Second-Line Option for Patients With Small Cell Lung Cancer
04/21/2025
Stephanie Holland
According to results from a retrospective analysis of a real-world cohort, temozolomide showed potential as a second-line option for patients with small cell lung cancer.
According to results from a retrospective analysis of a real-world cohort, temozolomide showed potential as a second-line option for patients with small cell lung cancer.
According to results from a...
04/21/2025
Oncology
News
Adding Pembrolizumab to Docetaxel Does Not Improve Survival Outcomes for Metastatic Castration-Resistant Prostate Cancer
04/21/2025
Stephanie Holland
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the...
04/21/2025
Oncology
News
Sacituzumab Govitecan Fails to Significantly Improve Survival in Advanced Urothelial Carcinoma
04/17/2025
Stephanie Holland
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis...
04/17/2025
Oncology
News
Rituximab Plus Lenalidomide Shows Durable Responses as Frontline Treatment for Patients With Follicular Lymphoma
04/16/2025
Emily Estrada
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide...
04/16/2025
Oncology
News
Tegafur-Uracil Maintenance Did Not Improve Survival for Patients With Locally Advanced Cervical Cancer
04/15/2025
Stephanie Holland
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the...
04/15/2025
Oncology
News
First-Line Durvalumab Plus Platinum-Etoposide for Patients With Extensive-Stage Small Cell Lung Cancer
04/14/2025
Stephanie Holland
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and...
04/14/2025
Oncology

Interactive Features

Quiz
Autologous Hematopoietic Cell Transplantation or CAR-T Therapy for Patients With Relapsed LBCL
09/30/2024
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to...
09/30/2024
Oncology
Quiz
Induction Therapy With High-Dose Chemo, Autologous HSCT in Patients With PCNSL
04/11/2024
04/11/2024
Oncology
Quiz
Blinatumomab After ASCT as a Treatment Option Among Patients With Relapsed DLBCL
02/27/2024
02/27/2024
Oncology
Quiz
Treating DLBCL With Tafasitamab Plus R-CHOP, With or Without Lenalidomide
12/15/2023
True or False: According to findings from the phase 1b First-MIND study, tafasitamab plus the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen with or without the addition of lenalidomide demonstrated...
True or False: According to findings from the phase 1b First-MIND study, tafasitamab plus the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen with or without the addition of lenalidomide demonstrated...
True or False: According to...
12/15/2023
Oncology
Quiz
Acalabrutinib Plus Danvatirsen for R/R DLBCL
12/05/2023
What were the key findings of the phase 1 PRISM trial, which investigated the use of BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen among patients with R/R DLBCL?
What were the key findings of the phase 1 PRISM trial, which investigated the use of BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen among patients with R/R DLBCL?
What were the key findings of...
12/05/2023
Oncology
Quiz
Standard vs 4-Cycle Regimen of R-CHOP for Non-Bulky, Low-Risk DLBCL
11/07/2023
According to findings from a phase 3 trial, how did a 4-cycle regimen of R-CHOP compare to the standard regimen in treating patients with non-bulky, low-risk DLBCL?
According to findings from a phase 3 trial, how did a 4-cycle regimen of R-CHOP compare to the standard regimen in treating patients with non-bulky, low-risk DLBCL?
According to findings from a...
11/07/2023
Oncology
Quiz
Simplified CIRS-Derived Comorbidity Index For DLBCL Patients Indicated for CAR T-Cell Therapy
10/18/2023
True or False: A simplified cumulative illness rating scale (CIRS)-derived comorbidity index was able to assess and predict adverse outcomes among patients with R/R DLBCL indicated for chimeric antigen receptor T-cell (CAR T) therapy.
True or False: A simplified cumulative illness rating scale (CIRS)-derived comorbidity index was able to assess and predict adverse outcomes among patients with R/R DLBCL indicated for chimeric antigen receptor T-cell (CAR T) therapy.
True or False: A simplified...
10/18/2023
Oncology
Quiz
Treating R/R DLBCL With Mosunetuzumab
10/03/2023
True or False: Mosunetuzumab demonstrated high efficacy and manageable safety among patients with R/R DLBCL, including those previously treated with CAR T-cell therapy.
True or False: Mosunetuzumab demonstrated high efficacy and manageable safety among patients with R/R DLBCL, including those previously treated with CAR T-cell therapy.
True or False: Mosunetuzumab...
10/03/2023
Oncology
Quiz
BET Inhibitor Trotabresib for Heavily-Pretreated R/R DLBCL
09/11/2023
True or False: Findings from a phase 1 trial indicated that BET protein inhibitor trotabresib monotherapy demonstrated potential, and antitumor activity, among patients with heavily pretreated relapsed/refractory DLBCL, as well as patients...
True or False: Findings from a phase 1 trial indicated that BET protein inhibitor trotabresib monotherapy demonstrated potential, and antitumor activity, among patients with heavily pretreated relapsed/refractory DLBCL, as well as patients...
True or False: Findings from a...
09/11/2023
Oncology
Quiz
High-Dose Chemotherapy and Auto-HSCT in First Remission for Intermediate/High-Risk Stage IV DLBCL
09/05/2023
True or False: High-dose chemotherapy (HDCT) followed by autologous hematopoietic stem-cell transplantation (auto-HSCT) in the first remission yielded effective results and improved prognosis among patients with intermediate/high-risk stage...
True or False: High-dose chemotherapy (HDCT) followed by autologous hematopoietic stem-cell transplantation (auto-HSCT) in the first remission yielded effective results and improved prognosis among patients with intermediate/high-risk stage...
True or False: High-dose...
09/05/2023
Oncology
Quiz
Inaticabtagene Autoleucel Therapy for R/R B-ALL
04/21/2025
Regarding the durability of remission achieved with inaticabtagene autoleucel therapy among patients with R/R B-ALL in a phase 2 trial, what was the median duration of remission reported?
Regarding the durability of remission achieved with inaticabtagene autoleucel therapy among patients with R/R B-ALL in a phase 2 trial, what was the median duration of remission reported?
Regarding the durability of...
04/21/2025
Oncology
Quiz
Dasatinib and Nilotinib as Second-Line Therapy for CML-CP
04/21/2025
In the real-world analysis comparing dasatinib and nilotinib as second-line therapies in CML-CP, what was the observed MMR rate at 12 months among patients treated with nilotinib?
In the real-world analysis comparing dasatinib and nilotinib as second-line therapies in CML-CP, what was the observed MMR rate at 12 months among patients treated with nilotinib?
In the real-world analysis...
04/21/2025
Oncology
Quiz
Pertuzumab Retreatment for Patients With HER2-Positive Breast Cancer
04/11/2025
Did the addition of pertuzumab retreatment to trastuzumab and physician’s choice chemotherapy improve survival among patients with HER2-positive, locally advanced or metastatic breast cancer?
Did the addition of pertuzumab retreatment to trastuzumab and physician’s choice chemotherapy improve survival among patients with HER2-positive, locally advanced or metastatic breast cancer?
Did the addition of pertuzumab...
04/11/2025
Oncology
Quiz
GPRC5D-Targeted CAR T-Cell Therapy for Multiple Myeloma
04/02/2025
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported...
04/02/2025
Oncology
Quiz
Central Nervous System Progression in Extensive-Stage Small Cell Lung Cancer
03/19/2025
Did atezolizumab plus etoposide and carboplatin delay time to central nervous system progression among patients with extensive-stage small cell lung cancer?
Did atezolizumab plus etoposide and carboplatin delay time to central nervous system progression among patients with extensive-stage small cell lung cancer?
Did atezolizumab plus etoposide...
03/19/2025
Oncology
Quiz
Talazoparib Plus Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
03/05/2025
According to results from the phase 2 SWOG S1929 study, what was the result of adding talazoparib to maintenance atezolizumab among patients with extensive-stage small cell lung cancer?
According to results from the phase 2 SWOG S1929 study, what was the result of adding talazoparib to maintenance atezolizumab among patients with extensive-stage small cell lung cancer?
According to results from the...
03/05/2025
Oncology
Quiz
Lurbinectedin for Patients With Platinum-Sensitive Small Cell Lung Cancer
02/10/2025
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did lurbinectedin demonstrate...
02/10/2025
Oncology
Quiz
Trastuzumab Emtansine for HER2-Positive Early Breast Cancer
02/07/2025
Did trastuzumab emtansine improve invasive disease-free survival compared to trastuzumab in patients with HER2-positive early breast cancer who had residual disease following neoadjuvant therapy?
Did trastuzumab emtansine improve invasive disease-free survival compared to trastuzumab in patients with HER2-positive early breast cancer who had residual disease following neoadjuvant therapy?
Did trastuzumab emtansine...
02/07/2025
Oncology
Quiz
Trilaciclib for Patients With Extensive-Stage Small Cell Lung Cancer
01/22/2025
Did the administration of trilaciclib prior to chemotherapy reduce the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer?
Did the administration of trilaciclib prior to chemotherapy reduce the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer?
Did the administration of...
01/22/2025
Oncology
Quiz
Lenvatinib Plus Pembrolizumab for Patients With Advanced or Recurrent Endometrial Cancer
12/20/2024
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line...
12/20/2024
Oncology

Recent News

News
Cytokine and Chemokines as Predictive Biomarkers of CAR-T Therapy Outcomes in Large B-Cell Lymphoma
04/11/2025
Emily Estrada
Plasma cytokines and chemokine levels may be used as predictive biomarkers of CAR-T therapy response and toxicity among patients with large B-cell lymphoma.
Plasma cytokines and chemokine levels may be used as predictive biomarkers of CAR-T therapy response and toxicity among patients with large B-cell lymphoma.
Plasma cytokines and chemokine...
04/11/2025
Oncology
News
Odronextamab Demonstrates Durability and Safety for Relapsed/Refractory DLBCL
04/09/2025
Emily Estrada
Treatment for relapsed/refractory diffuse large B-cell lymphoma with odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy.
Treatment for relapsed/refractory diffuse large B-cell lymphoma with odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy.
Treatment for...
04/09/2025
Oncology
News
Effect of Timing of Bispecific Antibody Treatment for Patients With B-Cell Lymphomas Relapsing After CAR-T
03/24/2025
Emily Estrada
Following CAR-T therapy relapse, study findings suggest the timing of bispecific antibody treatment administration may be associated with improved responses among patients with B-cell lymphomas.
Following CAR-T therapy relapse, study findings suggest the timing of bispecific antibody treatment administration may be associated with improved responses among patients with B-cell lymphomas.
Following CAR-T therapy relapse,...
03/24/2025
Oncology
News
Brentuximab Vedotin Plus Lenalidomide and Rituximab Improves Survival For Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
03/17/2025
Emily Estrada
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
For patients with...
03/17/2025
Oncology
News
Presence of Circulating Lymphoma Cells Associated With Worse Survival Outcomes for Patients With Newly Diagnosed DLBCL
01/16/2025
Emily Estrada
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are...
01/16/2025
Oncology
News
Autologous Hematopoietic Cell Transplantation Demonstrates Improved Outcomes Over CAR-T Among Patients With Relapsed LBCL Who Achieve Complete Remission
08/30/2024
Amber Denham
According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...
According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...
According to results from a...
08/30/2024
Oncology
News
IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology
News
Short Induction Therapy Followed by High-Dose Chemotherapy and Autologous HSCT Demonstrates Activity for Older Patients With Primary Diffuse Large B-Cell CNS Lymphoma
04/09/2024

Amber Denham

Amber Denham
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short...
04/09/2024
Oncology
News
Lisocabtagene Maraleucel Shows Continued Efficacy, Manageable Safety for Patients with R/R LBCL
02/28/2024

Amber Denham

Amber Denham
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up...
02/28/2024
Oncology
News
Polatuzumab Vedotin Plus Rituximab and Lenalidomide Efficacy Among Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
02/21/2024
Amber Denham
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with...
02/21/2024
Oncology
FDA Approval
FDA Approves Penpulimab for Patients With Non-Keratinizing Nasopharyngeal Carcinoma
04/24/2025
Stephanie Holland
On April 23, 2025, the FDA has approved penpulimab plus chemotherapy for patients with metastatic non-keratinizing nasopharyngeal carcinoma.
On April 23, 2025, the FDA has approved penpulimab plus chemotherapy for patients with metastatic non-keratinizing nasopharyngeal carcinoma.
On April 23, 2025, the FDA has...
04/24/2025
Oncology
News
Lenvatinib-Based Regimens Demonstrate Efficacy, Safety Among Pre-Treated Patients With Metastatic Renal Cell Carcinoma
04/24/2025
Stephanie Holland
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective...
04/24/2025
Oncology
News
Palbociclib Plus Endocrine Therapy May Prolong Progression-Free Survival for Premenopausal Patients With HR-Positive, HER2-Negative Breast Cancer
04/23/2025
Stephanie Holland
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to extended follow-up...
04/23/2025
Oncology
News
Trastuzumab Rezetecan for Patients With HER2-Mutated Non-Small Cell Lung Cancer
04/22/2025
Stephanie Holland
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the...
04/22/2025
Oncology
News
Temozolomide as Potential Second-Line Option for Patients With Small Cell Lung Cancer
04/21/2025
Stephanie Holland
According to results from a retrospective analysis of a real-world cohort, temozolomide showed potential as a second-line option for patients with small cell lung cancer.
According to results from a retrospective analysis of a real-world cohort, temozolomide showed potential as a second-line option for patients with small cell lung cancer.
According to results from a...
04/21/2025
Oncology
News
Adding Pembrolizumab to Docetaxel Does Not Improve Survival Outcomes for Metastatic Castration-Resistant Prostate Cancer
04/21/2025
Stephanie Holland
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the...
04/21/2025
Oncology
News
Sacituzumab Govitecan Fails to Significantly Improve Survival in Advanced Urothelial Carcinoma
04/17/2025
Stephanie Holland
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis...
04/17/2025
Oncology
News
Rituximab Plus Lenalidomide Shows Durable Responses as Frontline Treatment for Patients With Follicular Lymphoma
04/16/2025
Emily Estrada
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide...
04/16/2025
Oncology
News
Tegafur-Uracil Maintenance Did Not Improve Survival for Patients With Locally Advanced Cervical Cancer
04/15/2025
Stephanie Holland
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the...
04/15/2025
Oncology
News
First-Line Durvalumab Plus Platinum-Etoposide for Patients With Extensive-Stage Small Cell Lung Cancer
04/14/2025
Stephanie Holland
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and...
04/14/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use